Capgemini's Gen AI Breakthrough Accelerates Bioeconomy

Capgemini, a global leader in consulting, technology, and digital transformation services, has revealed a groundbreaking generative AI (gen AI)-driven methodology for protein engineering that promises to accelerate the bioeconomy. This innovative approach, which reduces data requirements for protein engineering by over 99%, has the potential to revolutionize industries such as healthcare, agriculture, and environmental science by driving critical scientific breakthroughs and fostering sustainable growth.

The bioeconomy, which relies on biological resources and processes, is expected to play a crucial role in addressing global challenges such as climate change, food security, and disease. However, data bottlenecks in research timelines have often hindered progress in this field. Capgemini's new methodology addresses this challenge by harnessing the power of gen AI to predict the most effective protein variants with significantly smaller datasets, enabling organizations to innovate even in resource-constrained environments.

Capgemini's approach has already demonstrated its potential in several critical use cases. For instance, the company enhanced the cutinase enzyme using its gen AI-driven approach, increasing its ability to break down PET plastic by 60%. This advancement can create novel, highly efficient, and cost-effective solutions to tackle global plastic waste, supporting sustainability objectives and helping lower operational costs associated with waste management.

Moreover, Capgemini reduced the number of experiments needed to identify an improved variant of the commonly cited Green Fluorescent Protein benchmark, from thousands to just 43 data points. This significantly cuts down on the time and resources typically required for experimental testing, enabling quicker deployment across various fields, including drug discovery, diagnostic tools, and bioengineering applications.



Capgemini's proprietary generative AI-driven approach opens the door to new opportunities for clients to develop innovative bio-based solutions, reduce costs, and accelerate their bio-journey in previously untapped areas. The company's end-to-end engineering biology and scale-up capabilities enable clients to derive significant business value and develop proprietary IP, moving away from traditional carbon-based approaches and fueling growth in the bioeconomy.

The global bioeconomy is expected to reach $7.4 trillion by 2025, driven by advancements in biotechnology, synthetic biology, and other related fields. Capgemini's breakthrough in protein engineering has the potential to accelerate this growth by unlocking new opportunities and driving innovation across various sectors.

In conclusion, Capgemini's gen AI-driven breakthrough in protein engineering addresses the challenges of data bottlenecks in research timelines and enables organizations to innovate more efficiently and effectively, even in resource-constrained environments. This approach has the potential to accelerate R&D, reduce costs, unlock new opportunities, and contribute to sustainability objectives, ultimately fostering the growth of the bioeconomy. As the global bioeconomy continues to expand, Capgemini's innovative methodology will play a crucial role in driving progress and addressing humanity's most pressing challenges.